Zhaoke Ophthalmology (HKG:6622) said China's National Medical Products Administration (NMPA) gave the marketing authorization for its Glaucoma eyedrops, Bimatoprost, according to a Thursday filing with the Hong Kong bourse.

Bimatoprost are preservative-free single-dose drops used to lower the intraocular pressure in patients with open-angle glaucoma and ocular hypertension.

The company's stocks were up by almost 3% in the early trading.

Price (HKD): $1.39, Change: $+0.040, Percent Change: +2.96%